Medindia

X

Iomai to Announce Third Quarter 2007 Financial Results and Host Webcast on Tuesday, November 13

Saturday, November 10, 2007 General News J E 4
Advertisement
GAITHERSBURG, Md., Nov. 9 Iomai Corporation(Nasdaq: IOMI) today announced that it will release third quarter 2007financial results before the markets open and hold a conference call and livewebcast to discuss corporate and clinical progress on Tuesday, Nov. 13, 2007at 11 a.m. Eastern Time.

Conference Call Details

To access the live conference call on Tuesday, Nov. 13 at 11 a.m. EasternTime via phone, please dial 866-510-0707 from the United States and Canada or617-597-5376 internationally. The conference ID is 85613352. Please dial inapproximately 10 minutes prior to the start of the call. A telephone replaywill be available beginning approximately one hour after the call through Nov.20 and may be accessed by dialing 888-286-8010 from the United States andCanada or 617-801-6888 internationally. The replay passcode is 49212414.

To access the live and subsequently archived webcast of the conferencecall, go to the Investor Relations section of the Company's website athttp://www.iomai.com . Please connect to the web site at least 15 minutesprior to the call to allow for any software download that may be necessary.The webcast is also being distributed through the Thomson StreetEventsNetwork. Individual investors can listen to the call athttp://www.earnings.com, Thomson's individual investor portal, powered byStreetEvents. Institutional investors can access the call via ThomsonStreetEvents (http://www.streetevents.com), a password-protected eventmanagement site.

About Iomai Corporation

Iomai Corporation discovers and develops vaccines and immune systemstimulants, delivered via a novel, needle-free technology calledtranscutaneous immunization (TCI). TCI taps into the unique benefits of amajor group of antigen-presenting cells found in the outer layers of the skin(Langerhans cells) to generate an enhanced immune response. Iomai isleveraging TCI to enhance the efficacy of existing vaccines, develop newvaccines that are viable only through transcutaneous administration and expandthe global vaccine market. Iomai currently has four product candidates indevelopment: three targeting influenza and pandemic flu and one to preventtravelers' diarrhea. For more information on Iomai, please visithttp://www.iomai.com.

SOURCE Iomai Corporation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
HollisterStier Offers Comfort With New ComforTen(T...
S
Five-Year Data Demonstrate Long-Term Efficacy and ...